" class="no-js "lang="en-US"> Manuela Mage - Medtech Alert
Friday, June 20, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Manuela Mage

Manuela Mage

About Manuela Mage

Manuela Mage brings an integrative approach to sessions. She is fluent in both English and Portuguese, and her multicultural background and extensive experience in individual and group therapy have taught her that the relationship is at the core of any successful therapeutic exchange. Manuela is also a certified yoga teacher (200h).

Related Story

Appointments

 Alma Raises $130M in Series D Funding led by Thoma Bravo to Advance its Mission to Simplify Access to High Quality

Alma Raises $130M in Series D Funding led by Thoma Bravo to Advance its Mission to Simplify Access to High Quality, Affordable Mental Health Care

August 26 2022

Alma, a membership-based network that helps independent mental health care providers accept insurance and build […]